Literature DB >> 10092301

Paramyxovirus infections in childhood and subsequent inflammatory bowel disease.

S M Montgomery1, D L Morris, R E Pounder, A J Wakefield.   

Abstract

BACKGROUND & AIMS: Measles virus has been implicated in the etiology of both inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis. Subacute sclerosing panencephalitis (SSPE) is caused by atypical measles infection. This study investigated the patterns of infection that are risks for SSPE, early infection and a close temporal relationship between measles and another infection, as potential risks for IBD.
METHODS: The data are from 7019 members of a nationally representative 1970 British Cohort Study. The ages of five childhood infections were recorded before onset of IBD symptoms. Diagnoses of IBD and insulin-dependent diabetes mellitus (IDDM), as a control disease, were identified by age 26 years.
RESULTS: Mumps infection before age 2 years was a risk for ulcerative colitis (odds ratio, 25.12; 95% confidence interval, 6. 35-99.36). Measles and mumps infections in the same year of life were significantly associated with ulcerative colitis and Crohn's disease, with odds ratios of 7.47 (2.42-23.06) and 4.27 (1.24-14.46), but not with IDDM. These relationships are independent of each other as well as sex, social class at birth, household crowding in childhood, and family history of IBD.
CONCLUSIONS: Atypical paramyxovirus infections in childhood may be risk factors for later IBD.

Entities:  

Mesh:

Year:  1999        PMID: 10092301     DOI: 10.1016/s0016-5085(99)70062-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  No evidence of persistent mumps virus infection in inflammatory bowel disease.

Authors:  M Iizuka; H Saito; M Yukawa; H Itou; T Shirasaka; M Chiba; T Fukushima; S Watanabe
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  MMR vaccine--worries are not justified.

Authors:  D A Elliman; H E Bedford
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

Review 3.  Detection of persistent measles virus infection in Crohn's disease: current status of experimental work.

Authors:  S Ghosh; E Armitage; D Wilson; P D Minor; M A Afzal
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

4.  Effect of Pentavac and measles-mumps-rubella (MMR) vaccination on the intestine.

Authors:  B Thjodleifsson; K Davídsdóttir; U Agnarsson; G Sigthórsson; M Kjeld; I Bjarnason
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

Review 5.  Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature.

Authors:  Natasha-A Koloski; Laurel Bret; Graham Radford-Smith
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

6.  Measles, mumps, rubella (MMR) vaccine.

Authors:  A P Dubey; S Banerjee
Journal:  Indian J Pediatr       Date:  2003-07       Impact factor: 1.967

7.  Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study.

Authors:  S Baron; D Turck; C Leplat; V Merle; C Gower-Rousseau; R Marti; T Yzet; E Lerebours; J-L Dupas; S Debeugny; J-L Salomez; A Cortot; J-F Colombel
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

8.  Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses.

Authors:  Suxiang Tong; Shur-Wern Wang Chern; Yan Li; Mark A Pallansch; Larry J Anderson
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

Review 9.  Pathogenesis of Crohn's disease: Bug or no bug.

Authors:  Marta Maia Bosca-Watts; Joan Tosca; Rosario Anton; Maria Mora; Miguel Minguez; Francisco Mora
Journal:  World J Gastrointest Pathophysiol       Date:  2015-02-15

10.  Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity.

Authors:  J E Aguirre; J H Winston; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2017-04-25       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.